$0.02
(Market cap
$2 Mln
Recently Viewed
Clear AllMarket cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.5
Debt to Equity
--
Book Value
$5.3
EPS
$-8
Face value
--
Shares outstanding
1,427,970
CFO
$-47.65 Mln
EBITDA
$-64.80 Mln
Net Profit
$-73.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adial Pharmaceuticals (ADIL)
| -71.3 | -14.1 | -72.7 | -91.0 | -80.2 | -74.1 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Adial Pharmaceuticals (ADIL)
| -78.2 | -45.4 | -65.4 | -91.9 | 58.8 | -29.5 | -52.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adial Pharmaceuticals (ADIL)
|
1.6 | 2.3 | 0.0 | -8.0 | -- | -170.7 | -- | 0.4 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 229.3 | 14,164.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist,... which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia. Read more
CEO, President & Director
Mr. Cary John Claiborne MBA
CEO, President & Director
Mr. Cary John Claiborne MBA
Headquarters
Glen Allen, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Adial Pharmaceuticals Inc (ADIL) is $1.58 (NASDAQ) as of 24-Apr-2026 16:00 EDT. Adial Pharmaceuticals Inc (ADIL) has given a return of -80.19% in the last 3 years.
Since, TTM earnings of Adial Pharmaceuticals Inc (ADIL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.03
|
0.04
|
|
2024
|
-0.38
|
1.24
|
|
2023
|
-0.27
|
0.46
|
|
2022
|
-0.02
|
0.07
|
|
2021
|
-0.14
|
0.77
|
The 52-week high and low of Adial Pharmaceuticals Inc (ADIL) are Rs 30.25 and Rs 1.51 as of 26-Apr-2026.
Adial Pharmaceuticals Inc (ADIL) has a market capitalisation of $ 2 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Adial Pharmaceuticals Inc (ADIL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.